GlassScriptPhysician profile
Eduardo Ramos
NPI 1790939148
$830.45
in general payments reported to CMS, 2019-2025
13 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $442 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.01 |
| Education | $220.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $177.94 | 2024 | |
| Abbvie INC. | $177.82 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $128.31 | 2024-2025 | Zerbaxa, Dificid |
| Mannkind Corporation | $67.31 | 2025 | |
| Viiv Healthcare Company | $47.81 | 2025 | Cabenuva, Dovato |
| Melinta Therapeutics, LLC | $45.84 | 2024 | Kimyrsa, Rezzayo |
| Astrazeneca Pharmaceuticals LP | $38.24 | 2025 | Airsupra |
| Pfizer INC. | $32.43 | 2025 | |
| Shionogi INC | $30.50 | 2025 | Fetroja |
| Qiagen, LLC | $28.01 | 2025 | |
| La Jolla Pharmaceutical Company | $22.51 | 2024 | Xerava |
| Paratek Pharmaceuticals, INC. | $18.16 | 2025 | Nuzyra |
| Daiichi Sankyo INC. | $15.57 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.